Alkermes plc (ALKS) - מזומן למניה

Alkermes plc (ALKS) is protected by patents on complex injectable formulations, which limits generic expansion. A sufficient liquidity surplus allows the company to fund R&D without external borrowing. The cash per share metric visualizes this margin of safety, and its current level is 4.54. The chronic nature of psychiatric disorders guarantees the company a stable revenue stream from patients' continuous medication use.
פילוחים אנליטיים של חברת Alkermes plc

This metric reflects the amount of free cash flow per common share, allowing for an assessment of the company's actual liquidity and internal reserves. For the biopharmaceutical business of Alkermes plc (ALKS), with its patent portfolio and royalties, an analysis of the issuer's cash per share via the GURU.Markets platform reveals a balance between R&D investments and operational efficiency, determining the fundamental stability of the business.